Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
Ellen M. Apperloo(Dialyse Centrum Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Michelle J. Pena(University Medical Center Groningen), Petra Denig(University Medical Center Groningen), Dick de Zeeuw(University Medical Center Groningen)
Cited by 10
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k